Akademik Veri Yönetim Sistemi
Türkiye Çocuk Hastalıkları Dergisi, cilt.14, sa.6, ss.507-511, 2020 (Hakemli Dergi)
Objective: This study evaluates total erythrocyte, random platelet and apheresis platelet suspension requirement in pediatric acute myeloid leukemia (AML) patients in relation to ongoing chemotherapy (CT) regimens.Material and Methods: A total of 37 pediatric patients diagnosed with AML were included in this retrospective study. Data on patient demographics (age, gender), age at diagnosis, type of CT protocol, completion of CT protocol and amount of blood product use (erythrocytes, apheresis platelet and random platelet) and survival during CT were retrieved from hospital records. Results: The total number of erythrocytes, apheresis platelets and random platelets received by 37 AML patients from the date of diagnosis were 1275 (mean (min-max): 27 (10-102) bags), 1287(mean (min-max): 25 (-99 bags) and 1237(mean (min-max): 20 (7-139) bags), respectively. AIE as followed by maintenance treatment was associated with the highest amount of erthryocyte (p<0.001) and apheresis platelet (p<0.001) use when compared to other CT regimens, while maintenance treatment as followed by AIE was associated with the highest amount of random platelet use (p=0.008) as compared with other CT regimens. No significant difference was noted between AI and haM protocols in terms of blood product use, while apheresis platelet and random platelet use were lowest with HAM treatment (p<0.001 and p=0.008, respectively).Conclusion: In conclusion, our findings indicate a great amount blood product transfusion to be required in children with AML under chemotherapy and emphasize the likelihood of transfusion need to alter with respect to ongoing CT regimen.